WO2015172077A1 - Acides polygalacturoniques o-acétylés de haut poids moléculaire et leur utilisation en tant que vaccin polysaccharidique contre le vi - Google Patents
Acides polygalacturoniques o-acétylés de haut poids moléculaire et leur utilisation en tant que vaccin polysaccharidique contre le vi Download PDFInfo
- Publication number
- WO2015172077A1 WO2015172077A1 PCT/US2015/029979 US2015029979W WO2015172077A1 WO 2015172077 A1 WO2015172077 A1 WO 2015172077A1 US 2015029979 W US2015029979 W US 2015029979W WO 2015172077 A1 WO2015172077 A1 WO 2015172077A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hpga
- oac
- acceptable salt
- pharmaceutically acceptable
- molecular weight
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- acetylation can be achieved by other processes, including the one described by Carson and aclay, J. Am. Chem. Soc, 88:1015-1017 (1946).
- O-acetylation or "G-acetylated” refers to addition of acetyl groups at the C2 and C3 positions of a sugar residue. The maximum degree of O-acetylation (200%) is reached when both the C2 and C3 positions of each sugar residue are acetylated.
- OAc-HPGA possesses the boosting effect or memory immune response, exhibiting more than a 2-fold rise in antibody titers upon the second immunization, No such boosting effect was observed with the Vi vaccine (Typhim Vi ® ) tested in parallel.
- the polysaccharide antigens are known to be T-independent and lack the immune memory or boosting effect.
- the memory or boosting immune response is only achieved with polysaccharide antigens by conjugating them with a protein carrier.
- OAc- HPGA is highly unique in possessing the boosting effect on its own without any conjugation, which is likely due to its novel chemical properties.
- the process modified from the Schweiger method, consists of six simple steps (Fig, 2). Compared to the original Schweiger method, it is much simplified by the two distinct properties of GelSite ® - acid gelation and insolubility in water in its acid form.
- the first step is to convert the substrate or GelSite ® to its acid form from the sodium salt form by rinsing in dilute HCI and then glacial acetic acid.
- One of the novel properties of GelSite ® is that it gels efficiently at low H, forming strong acid gel beads or strands which can withstand the down-stream steps.
- the original Schweiger method first prepared calcium precipitates prior to acid wash steps. This is therefore not necessary and eliminated for O-acetylation of GelSite ® .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580023307.6A CN106459225A (zh) | 2014-05-08 | 2015-05-08 | O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途 |
EP15723634.0A EP3140324A1 (fr) | 2014-05-08 | 2015-05-08 | Acides polygalacturoniques o-acétylés de haut poids moléculaire et leur utilisation en tant que vaccin polysaccharidique contre le vi |
AU2015255693A AU2015255693A1 (en) | 2014-05-08 | 2015-05-08 | O-acetylated high molecular weight polygalacturonic acids and their use as Vi polysaccharide vaccine |
CA2946900A CA2946900A1 (fr) | 2014-05-08 | 2015-05-08 | Acides polygalacturoniques o-acetyles de haut poids moleculaire et leur utilisation en tant que vaccin polysaccharidique contre le vi |
JP2016566668A JP2017514961A (ja) | 2014-05-08 | 2015-05-08 | O−アセチル化高分子ポリガラクツロン酸およびVi多糖類ワクチンとしてのその利用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461990493P | 2014-05-08 | 2014-05-08 | |
US61/990,493 | 2014-05-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015172077A1 true WO2015172077A1 (fr) | 2015-11-12 |
WO2015172077A8 WO2015172077A8 (fr) | 2016-01-28 |
Family
ID=53190060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/029979 WO2015172077A1 (fr) | 2014-05-08 | 2015-05-08 | Acides polygalacturoniques o-acétylés de haut poids moléculaire et leur utilisation en tant que vaccin polysaccharidique contre le vi |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3140324A1 (fr) |
JP (1) | JP2017514961A (fr) |
CN (1) | CN106459225A (fr) |
AU (1) | AU2015255693A1 (fr) |
CA (1) | CA2946900A1 (fr) |
WO (1) | WO2015172077A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5929051A (en) | 1998-05-13 | 1999-07-27 | Carrington Laboratories, Inc. | Aloe pectins |
US7691986B2 (en) | 1998-05-13 | 2010-04-06 | Nanotherapeutics, Inc. | High molecular weight, low methoxyl pectins, and their production and uses |
-
2015
- 2015-05-08 WO PCT/US2015/029979 patent/WO2015172077A1/fr active Application Filing
- 2015-05-08 CA CA2946900A patent/CA2946900A1/fr not_active Abandoned
- 2015-05-08 JP JP2016566668A patent/JP2017514961A/ja active Pending
- 2015-05-08 AU AU2015255693A patent/AU2015255693A1/en not_active Abandoned
- 2015-05-08 CN CN201580023307.6A patent/CN106459225A/zh active Pending
- 2015-05-08 EP EP15723634.0A patent/EP3140324A1/fr not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5929051A (en) | 1998-05-13 | 1999-07-27 | Carrington Laboratories, Inc. | Aloe pectins |
US7691986B2 (en) | 1998-05-13 | 2010-04-06 | Nanotherapeutics, Inc. | High molecular weight, low methoxyl pectins, and their production and uses |
US7705135B2 (en) | 1998-05-13 | 2010-04-27 | Nanotherapeutics, Inc. | Pharmaceutical compositions comprising aloe pectins, and methods for their production and use |
Non-Patent Citations (20)
Title |
---|
B SZEWCZYK ET AL: "Immunochemical properties of Vi antigen from Salmonella typhi Ty2: presence of two antigenic determinants", INFECTION AND IMMUNITY, vol. 29, no. 2, 1 August 1980 (1980-08-01), pages 539 - 544, XP055206183, ISSN: 0019-9567 * |
CARSON; MACLAY, J. AM. CHEM. SOC., vol. 68, 1946, pages 1015 - 1017 |
GONZALEZ-FERNANDEZ ET AL., VACCINE, vol. 26, 2008, pages 292 - 300 |
HESTRIN, J. BIOL. CHEM., vol. 180, 1949, pages 249 - 261 |
JARVIS ET AL., J. BACTERIOL., vol. 94, 1967, pages 1406 - 1410 |
KOSSACZKA ET AL., INFECT. IMMUN., vol. 67, 1997, pages 5806 - 5810 |
MARTIN ET AL., J. BACTERIOL., vol. 94, 1967, pages 1411 - 1416 |
RICHARD G. SCHWEIGER: "Acetyl Pectates and Their Reactivity with Polyvalent Metal Ions 1", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 29, no. 10, 1 October 1964 (1964-10-01), pages 2973 - 2975, XP055205872, ISSN: 0022-3263, DOI: 10.1021/jo01033a041 * |
RIJPKEMA ET AL., BIOLOGICALS, vol. 32, 2004, pages 11 - 6 |
SCHWEIGER, J. ORG. CHEM, vol. 29, 1964, pages 2973 - 2975 |
SZEWCZYK; TAYLOR, INFECT. IMMUN, vol. 29, 1980, pages 539 - 544 |
SZEWCZYK; TAYLOR, INFECT. LMMUN., vol. 29, 1980, pages 539 - 544 |
SZU ET AL., ENZYMOL., vol. 363, 2003, pages 552 - 567 |
SZU ET AL., INFECT IMMUN., vol. 62, 1994, pages 5545 - 5549 |
SZU ET AL., INFECT. IMMUN, vol. 59, 1991, pages 4555 - 4561 |
SZU ET AL., INFECT. IMMUN., vol. 59, 1991, pages 4555 - 4561 |
SZU ET AL., INFECT. IMMUN., vol. 62, 1994, pages 5545 - 5549 |
SZU S C ET AL: "Synthesis and Some Immunologic Properties of an O-Acetyl Pectin [Poly(1->4)-.alpha.-D-GalpA]-Protein Conjugate as a Vaccine for Typhoid Fever", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 62, no. 12, 1 December 1994 (1994-12-01), pages 5545 - 5549, XP008120217, ISSN: 0019-9567 * |
SZU; BYSTRICKY, ENZYMOL, vol. 363, 2003, pages 552 - 567 |
WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION, 1993 |
Also Published As
Publication number | Publication date |
---|---|
AU2015255693A1 (en) | 2016-11-03 |
JP2017514961A (ja) | 2017-06-08 |
CN106459225A (zh) | 2017-02-22 |
EP3140324A1 (fr) | 2017-03-15 |
WO2015172077A8 (fr) | 2016-01-28 |
CA2946900A1 (fr) | 2015-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101446238B1 (ko) | 단백질 매트릭스 백신 및 그의 제조방법 및 백신 투여방법 | |
CA2836251C (fr) | Compositions de vaccin a matrice de proteine incluant des polycations | |
US20120231086A1 (en) | Protein matrix vaccines of improved immunogenicity | |
AU2004251734B2 (en) | Vaccines against group Y neisseria meningitidis and meningococcal combinations thereof | |
RU2563354C2 (ru) | Адъювант на основе низкомолекулярного пептидогликана клеточной стенки бактерий | |
Ni et al. | Development of a synthetic Vi polysaccharide vaccine for typhoid fever | |
AU2018290298B2 (en) | Immunogenic compositions | |
EP3140324A1 (fr) | Acides polygalacturoniques o-acétylés de haut poids moléculaire et leur utilisation en tant que vaccin polysaccharidique contre le vi | |
WO2022212827A2 (fr) | Méthodes et compositions pour traiter des infections à clostridioides difficile | |
안소정 | Development of efficient Vi polysaccharide conjugate vaccine and its vaccination strategy for prevention of typhoid fever | |
WO2009033269A1 (fr) | Nouveaux polysaccharides immunogènes issus de alloiococcus otitidis et synthèse d'un vaccin glycoconjugué correspondant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15723634 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2946900 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015255693 Country of ref document: AU Date of ref document: 20150508 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016566668 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015723634 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015723634 Country of ref document: EP |